Pharmanest Appoints Alan Raffensperger as Chairman of the Board
News Nov 02, 2012
Pharmanest AB has announced that Alan Raffensperger, Per Langö and Gunilla Ekström have been elected as new members of the Board. Alan Raffensperger was elected Chairman.
The Board of Pharmanest has hereby gained comprehensive experience in the commercialization of new, innovative products and is well prepared to progress the candidate drug SHACT, for pain relief in gynecological procedures.
Alan Raffensperger has extensive international experience in management, business development and strategic planning in the Life Science sector.
He is currently Chief Operating Officer (COO) of SOBI AB and has previously held the position as CEO of BeneChill AB and senior positions at Amgen, Roche and Pharmacia.
Per Langö has extensive industry experience from the global pharmaceutical and medical device industry with focus on marketing and sales, product development and business development.
He is currently Head of Galderma's global marketing and strategic development within aesthetics and medical technology and has previously held senior positions at Q-Med.
Gunilla Ekström holds an M.D. and Ph.D. from Karolinska Institutet. Dr. Ekström has more than 20 years of experience in drug development from senior positions at Astra Pain Control, AstraZeneca and Orexo. Since June 1, 2012, she works as VP Operations at Karolinska Development AB.
The election of the new members took place at an extraordinary general meeting on October 5, 2012. Other board members are Gunvor Ekman-Orderberg and Arne Brodin.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE